As per the report titled ‘U.S. Compounding Pharmacies Market Size By Pharmacy Type, By Sterility, By Product By Application, By Compounding Type By Therapeutic Area Industry Analysis Report, Application Potential, Competitive Market Share & Forecast, 2020 - 2026’, available with Market Study Report, U.S. compounding pharmacies market is anticipated to record a healthy growth through 2026.
 

Increasing number of patients suffering from various diseases that require specialized formulations is the primary growth driver of U.S. compounding pharmacies market. Compounding pharmacies prepare drugs which have been prescribed by doctors for patients with requirements that are usually not met by commercially available drugs.
 

Based on the pharmacy type, the market is bifurcated into 503A and 503B, wherein the previous segment is projected to expand at 3% CAGR during the forecast period. However, drug production limitations imposed by the government curbs the segment growth.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/1294885/
 

In terms of sterility, sterile segment accounted for 29% market share in 2019 and is expected to show modest growth in the coming years. Rising number of patients suffering from illness and escalating deaths due to inferior sterile compounded preparations are fueling demand for high quality sterile compounded drugs.
 

Elaborating on the product, ophthalmic segment is estimated to grow with a CAGR of 5% throughout the forecast duration. Increasing age-related disorders such as cataract, glaucoma, diabetic retinopathy, and visual impairment by macular degeneration are bolstering the demand for ophthalmic compounded drugs.
 

With respect to the compounding type, PIA (pharmaceutical ingredient alteration) segment generated USD 1.6 billion in 2019 and is poised to see modest gains in the forthcoming years. The growth is attributable to the benefit of selective drug compound replacement for the allergic patients.
 

Speaking of the application spectrum, U.S. compounding pharmacies market share from adult segment recorded a valuation of USD 2 billion in 2019. Escalating demand for compounded drugs for treatment of cardiovascular diseases among adults in tandem with the growing elderly population base who are prone to acquiring such diseases will continue to foster the segment growth in the ensuing years.
 

Considering the therapeutic area, specialty drugs segment estimated to register 6% CAGR during 2020- 2026, due to growing availability of gluten-free, soy-free, alcohol-free, as well as preservative-free compounded specialty drugs in varying dosage forms.
 

Key players operating in U.S compounding pharmacies market are US Compounding, Fagron, B. Braun Medical, Dougherty's Pharmacy, Inc., Institutional Pharmacy Solutions, Fresenius Kabi AG, ImprimisRx (Harrow Health, Inc.), PharMEDium Healthcare Holdings, McGuff Compounding Pharmacy Services Inc., Pencol Compounding Pharmacy, Rx3 Compounding Pharmacy, Wedgewood Village Pharmacy, Inc., and  Triangle Compounding Pharmacies (Panaceutics).